Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Upadacitinib ER by AbbVie for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease): Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Pre-Registration for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease)....
Upadacitinib ER by AbbVie for Vitiligo: Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase III for Vitiligo. According to GlobalData, Phase III...
Upadacitinib ER by AbbVie for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease): Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase III for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)....
Upadacitinib ER by AbbVie for Alopecia Areata: Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase III for Alopecia Areata. According to GlobalData, Phase...
Upadacitinib ER by AbbVie for Oligoarticular Idiopathic Juvenile Arthritis: Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase I for Oligoarticular Idiopathic Juvenile Arthritis. According to...
Upadacitinib ER by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase III for Systemic Lupus Erythematosus. According to GlobalData,...